Masitinib (17) is a multi-kinase inhibitor (Table 1) that also inhibits fibroblast growth factor receptors and has been identified as a synaptoprotective agent in a dual amyloid precursor protein (APP)/presenilin 1 (PSEN1) mouse model of Alzheimer’s disease (AD) [106,111]. Here, PSEN1 is linked to early-onset autosomal dominant Alzheimer disease.